Evaluation of Cardiovascular Disease Risk in HIV-1-Infected Patients Treated with Darunavir.

ABSTRACT:

Introduction

We evaluated cardiovascular disease (CVD) risk associated with darunavir treatment and examined the demographic/clinical characteristics of darunavir users based on data from Janssen-sponsored clinical trials, post-marketing pharmacovigilance databases, and administrative claims databases.

Methods

First, selected CVD events [myocardial infarction, stroke, sudden death, invasive cardiovascular procedures (coronary artery angioplasty or bypass, or carotid endarterectomy)] were analyzed in 19 Janssen-sponsored phase 2-4 studies (incidence rates estimated from pooled data; 95% confidence intervals derived from Poisson distribution). Second, analyses were conducted to identify spontaneously reported CVD events in post-marketing pharmacovigilance databases and evaluat

SUBMITTER: Opsomer M 

PROVIDER: S-EPMC6131121 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature